Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios.
